相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
Nicholas Turner et al.
BREAST CANCER RESEARCH AND TREATMENT (2022)
Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Brian W. Labadie et al.
CANCER MANAGEMENT AND RESEARCH (2022)
Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.
Christopher Sweeney et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
Mingxiang Liao et al.
CLINICAL PHARMACOKINETICS (2022)
Mitigating ipatasertib-induced glucose increase through dose and meal timing modifications
Dhruvitkumar S. Sutaria et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.
Johann S. De Bono et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
C. N. Sternberg et al.
ANNALS OF ONCOLOGY (2021)
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
Shannon N. Westin et al.
CLINICAL CANCER RESEARCH (2021)
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients
Kenta Yoshida et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Role of Akt Activation in PARP Inhibitor Resistance in Cancer
Ferenc Gallyas et al.
CANCERS (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers
Timothy A. Yap et al.
CANCER DISCOVERY (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
Philipp Nuhn et al.
EUROPEAN UROLOGY (2019)
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2019)
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2019)
LBA50Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
M R Smith et al.
ANNALS OF ONCOLOGY (2019)
Management of toxicity to isoform α-specific PI3K inhibitors
S. E. Nunnery et al.
ANNALS OF ONCOLOGY (2019)
Metastatic Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2017)
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
Cristina Saura et al.
CANCER DISCOVERY (2017)
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
Charles-Andre Philip et al.
BMC CANCER (2017)
Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways
Yingmei Wang et al.
GYNECOLOGIC ONCOLOGY (2016)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Konstantin J. Dedes et al.
CELL CYCLE (2011)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer
S Oudard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
M Esteller et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)